key: cord-0960202-5e3fmv2m
authors: Anastasi, Emanuela; Marziali, Marco; Preziosi, Adele; Berardelli, Elena; Losardo, Anna Annunziata; Ribersani, Michela; Pugliese, Pellegrina; Farina, Antonella; Mancini, Patrizia; Angeloni, Antonio
title: Humoral Immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in Thalassemia Major patients
date: 2022-04-04
journal: Microbes Infect
DOI: 10.1016/j.micinf.2022.104976
sha: 204e34b3e08d1db71bb98cd907830d02ce2c57a2
doc_id: 960202
cord_uid: 5e3fmv2m

One of the most urgent needs worldwide is to vaccinate against SARS-CoV-2 as many people as possible. We evaluated humoral response to Comirnaty vaccine in Thalassemia Major patients (TM). We measured SARS-CoV-2–specific antibodies against Spike protein in 57 TM patients and 58 healthy blood donors (HBD). TM and HBD subjects revealed a homogeneous serological response to the Comirnaty (Mean±SD; TM=1917,21±1384,49; HBD=2039,81±1064,44; p=0,5884). No statistically significant differences were observed among two groups. Interestingly, we observed in 73.3% of asplenic patients Ab-S titres above 800 BAU, whereas only in 26% of non splenectomized patients showed Ab-S titres above 800 BAU). This differences were statistically significant p< 0.039. Further measurement on other Ab types was needed for better understanding humoral response to Comirnaty.

The efficiency of the humoral response to the new vaccines against SARS-CoV-2 is currently a topic 53 of great scientific relevance and represents an important aspect to monitor viral spread and reduce the 54 access in intensive care unit [1, 2] Anti-Spike antibodies (anti-S ab) and anti-Nucleocapsid antibodies 55 (anti-N ab) are, at the current time, the best tools to monitor humoral response to SARS-CoV-2 56 infection [ 3, 4] . Vaccination-induced immunity in comparison to natural infection-induced immunity, 57 provides a strong reason why in vulnerable patients vaccination is needed.

Most of the studies describing humoral response to natural infection suggest that the persistence of 59 these antibodies is limited to few months [ 5,6].

Therefore, one of the most urgent needs worldwide is to vaccinate against SARS-CoV-2 as many 61 people as possible.

Although previous studies do not indicate a greater severity of Covid-19 in β-thalassemia patients, it is Furthermore, monitoring the vaccinated population is the main tool to understand the effectiveness of 

Our study has some strengths: this is the first study examining a large cohort of thalassemia patients 149 with no comorbidities affecting humoral response; the same vaccine protocol was adopted for all 150 patients and finally identical withdrawal times were applied to all patients.

On the other hand, limitation of this study is owed to the short endpoint after the second dose of 152 vaccine thus, the long-term immune response was not investigated. To this purpose, further studies 153 are ongoing to evaluate cell-mediated immune response. 

Konstantinos 187 I Gourgoulianis

Angeloni 190 A. COVID-19 pneumonia and pulmonary microembolism in a patient with B-thalassemia major

Epub ahead of print

Post-splenectomy and hyposplenic states

Immune 202 profile of asplenic patients following single or double vaccine administration: A longitudinal cross-203 sectional study. Ulus Cerrahi Derg

Hyposplenism: a comprehensive review. Part I: basic concepts 206 and causes

Ab-S (BAU/mL) Statistical analysis was carried out using t test